invest summari ep beat strong growth key drug
ahead import pipelin data reiter ow rate
month price target share think respect earn growth
driven innov medicin pipelin advanc return capit
sharehold industri averag underappreci
therefor multipl expans upward earn revis drive
 takeaway support posit thesi revenu
reflect oper growth driven eliqui ibranc prevnar
xeljanz xtandi well biosimilar emerg market
perform growth driver partial off-set product
declin legaci establish product develop market on-going
oper eliqui global oper primarili driven
continu increas adopt non-valvular atrial fibril well
oral anti-coagul market share gain ibranc ou oper
primarili driven continu uptak develop eu decemb
launch japan prevnar primarili due higher
govern purchas pediatr indic xeljanz global
oper primarili driven continu uptak ra xtandi
 primarili due continu uptak metastat
indic narrow financi guidanc result lower-than-anticip
eh revenu primarili due continu legaci hospira sip product shortag
 fx forgiv neither unexpect view
new ceo albert bourla assum role januari
call reiter lot key goal alreadi set forth
includ blockbust year organ compani busi
larg scale
report adjust dilut ep factset
consensu higher estim narrow ep
guidanc factset consensu
midpoint updat ep guidanc rang unchang juli
ep guidanc reflect anticip share repurchas total
adjust financi model report increas
 valuat use blend dcf multipl ev/ebitda analysi get
price target
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
sever potenti risk invest thesi price target
product repres signific portion sale could face gener
competit current portfolio product may face competit cannib
pipelin introduct new competit could diminish price
power exist drug record direct product and/or allianc revenu
billion nine biopharmaceut product prevnar lyrica
ibranc eliqui enbrel lipitor xeljanz viagra sutent account total
revenu product pfizer major product subject
problem loss patent protect applic chang prescript growth rate
affect doctor patient confid pressur exist competit product chang
label access pressur new more-effect treatment introduc
advers impact revenu could signific
pipelin delay failur and/or higher-than-forecast competit gener
may continu face access challeng biosimilar product market
biosimilar product may receiv access pariti innov product remain
disadvantag posit exampl inflectra/remsima experienc access challeng
risk relat strateg acquisit success recent acquisit
hospira anacor mediv astrazeneca small molecul anti-infect busi
depend larg part compani abil realiz anticip benefit combin
busi exist segment exampl may fail achiev
anticip cost save acquisit hospira cost save within
expect time frame accret impact anticip acquisit hospira
anacor mediv may realiz may delay also may fail gener
revenu growth acquir busi expect time enter
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull
bear case scenario base analysi estim likelihood stock worth
next month
exhibit bull bear base case scenario analysi
cantor fitzgerald research compani reportsbul casesal ibranc eliqui xeljanzand key drug exceed expectationspipelin advanc exceed expectationsstrateg accret scenario casesal ibranc eliqui xeljanzand key drug line expectationspipelin advanc line expectationsno scenario casesal ibranc eliqui xeljanzand key drug expectationspipelin advanc expectationsno scenario exhibit varianc analysi
amount chang yoyamount chang yoyvariancecommentstot favor impact foreign exchang lower sale volum higher cog portfolio gross favor impact foreign exchang benefit cost-reduct product complet certain tanezumab studi decreas spend biosimilar oper non oper increas dividend incom collabor out-licens arrang sale compound/product right royalti pre-tax tax net dilut share adjust dilut cantor fitzgerald research compani reportsactualcantor
exhibit catalyst event calendar
datedriverupcom palbociclib phase pallet data neoadjuv newli diagnos breast cancer novemb date alk-posit nsclc decemb smo inhibitor pdufa date acut myeloid detail data phase alta studi hemophilia co-promot exact sciencesl enzalutamid adtphas arch data metastat hormon sensit tfpi mab phase data hemophilia triplet bavencio data solid interim analysi prophylact vaccin phase data invas group streptococcu updat patent combophas data pancreat ductal agonist phase data rheumatoid data rheumatoid sunitinib ema decis adjuv treatment high risk essenti healthprogress remedi effort address suppli epogen biosimilar healthcar businessannounc decis potenti strateg alternativesbi end loss isavuconazol addit data rheumatoid monotherapi combo w/ phase javelin ovarian data platinum-resistant/refractori ovarian javelin gastric data gastric mainten avelumab best support care phase javelin bladder data bladder mainten bourla succeed biosimilar trastuzumab bsufa biosimilar bevacizumab bsufa data sickl avelumab inlyta axitinib phase javelin renal data renal cell carcinoma multival pneumococc conjug vaccin phase therapeut vaccin phase data vaccine-bas immunotherapi regimen prostat mini-dystrophin gene therapi phase earli data duchenn muscular dystrophi phase data oa/clbp phase data oa/clbp safeti data oa/clbp pain us eu jade moder sever ad top-line readoutspr asept process map facilitygroundbreak portag michigansourc cantor fitzgerald research compani report exhibit catalyst event calendar continu
datedriverupcom biosimilar rituximab bsufa therapeuticsent phase partial agonist parkinson diseas alk-posit smo inhibitor launch acut myeloid talazoparib launch gbrca-posit breast talazoparib phase data metastat phase data data moder sever ulcer combo w/ and/or follow chemo phase javelin ovarian data epitheli ovarian cancer javelin lung data nsclc vaccinephas data respiratori syncyti anti data atop enzalutamid leuprolidephas embark data nonmetastat palbociclib phase palla data intermediate-risk earli breast month stay expiresend palbociclib phase penelop data high-risk earli breast palbociclib phase patina data breast coagul factor ix data hemophilia readout cancer prophylact vaccin phase strive data aureu data ankylos talazoparib avelumabphas javelin parp medley data local advanc metastat solid data crohn prophylact vaccin phase clover data clostridium difficil patent asept process map facilitycomplet construct portag combo w/ soc chemoradi crt phase javelin head neck data head neck talazoparib avelumabphas javelin brca/atm data metastat solid tumor brca atm eu patent eu patent expirationend co-promot talazoparib w/ novel hormon therapi nht phase data metastat castration-resist talazoparib phase javelin ovarian parp data previous untreat advanc ovarian patent patent palbociclib us/major eu/japan patent palbociclib major eu patent asept process map facilitybegin product portag patent eu/japan patent patent eu patent patent eu/japan patent eu patent enzalutamid us patent patent eu patent patent patent patent patent avelumab major eu/japan patent avelumab us patent expirationsourc cantor fitzgerald research compani report exhibit cantor estim versu manag guidanc
exhibit incom statement analysi
exhibit margin analysi
exhibit quarterli sale analysi
exhibit annual sale analysi
exhibit analysi
exhibit balanc sheet analysi
pfizer inc engag discoveri develop manufactur healthcar product special medicin vaccin
